SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its anticipated inclusion in the S&P 500, sparking excitement among investors who foresee potential institutional investment and a price surge akin to Palantir's after its inclusion. The community is actively discussing potential short squeezes, target prices, and the impact of the upcoming company summit and potential Federal Reserve rate cuts on the stock's performance. Some investors are cautioning against excessive optimism, citing previous instances where stocks experienced declines post-inclusion.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as holders actively discuss earning Solana ($SOL.X) rewards simply by holding the token, highlighting its potential as a passive income source. The community is also excited about the upcoming Bare Knuckle Fighting Championship (BKFC) event featuring Kimbo Slice Jr., who will be representing $IMG.X, signaling a move towards broader brand visibility and community engagement.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is trending as investors weigh its dividend yield against recent market performance, with some expressing frustration over underperformance compared to growth-focused ETFs. The community is actively debating whether to hold SCHD for long-term income or rotate into higher-growth opportunities, especially as some point to its heavy weighting in energy and healthcare sectors. Recent discussions also highlight anticipation for the next dividend announcement and how broader economic factors like interest rate cuts and potential tariffs might impact the ETF.

Aventus

Aventus is trending, with community members highlighting a new partnership with The Truth Network. Bullish sentiment seems to be building with anticipation of a potential listing on a top 10 exchange. Some traders are pointing to the token's low market cap and limited supply as factors that could drive price appreciation.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors discuss its potential for growth, particularly following a recent analyst upgrade from Raymond James. Community members are focused on price targets, with some anticipating a rise to $25 next week and $50 in the near future. The stock's behavior around the $22 level is also a key talking point, with many hoping it can sustain gains.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around its potential, citing ongoing developments and a strong, active community. The coin, built on the Solana network, is experiencing increased attention, with community members celebrating new all-time highs. Discussions also highlight upcoming airdrops and staking features, generating excitement for the project's future.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as traders discuss its potential upside and key resistance levels, with some eyeing it as a safe haven amid market uncertainty. Community members are actively considering options strategies and anticipating a run toward specific price targets, while also monitoring news related to analyst ratings and potential tariff impacts. Broader discussions involve P&G's role as a defensive stock and its established history of dividend increases.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to its recent $100 million private placement and strategic move into Injective ($INJ.X) digital assets. The community is actively discussing potential short squeezes and the stock's volatile price action, while also debating the long-term prospects of PAPL given its financial situation. Some traders are wary of dilution, while others see significant upside potential due to the small float and high borrowing costs.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is currently a hot topic with community members debating its potential for growth and whether it's undervalued compared to other cryptocurrencies like ETH. Discussions also involve staking rewards and upcoming catalysts, such as potential ETF approvals. Despite mixed sentiment, some believe DOT is poised for a significant rally, while others express concerns about its performance.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as chatter revolves around potential acquisition bids and analyst optimism for their drug candidate, AXPAXLI, despite recent market volatility. Community members speculate on buyout prices and partnerships, focusing on the upcoming SOL-1 data and its potential impact on valuation. Some traders are weighing OCUL against competitors in the wet AMD space, while others discuss the broader biotech sector trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Therma Bright, Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:<ol><li>Managing symptoms of post-thrombotic syndrome (PTS)</li><li>Preventing primary thrombosis</li><li>Treating lymphedema</li><li>Reducing post-operative pain and swelling</li><li>Alleviating leg swelling caused by vascular insufficiency</li><li>Treating varicose veins</li><li>Managing chronic venous insufficiency</li><li>Enhancing blood circulation</li><li>Addressing intermittent claudication</li></ol>All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

Therma Bright (TBRIF) Stock Skyrockets After Medicare and Medicaid Milestone, Enters Multi-Billion-Dollar Market

Therma Bright’s Venowave VW5 achieves a Medicare code, boosting its market reach in DVT treatment. With new partnerships and a diverse product pipeline, the company is set for significant growth.

Therma Bright Gains Medicare Milestone, Expands into $1.5B Market

public companies

Therma Bright’s stock surges as its Venowave VW5 device secures a crucial Medicare and Medicaid designation, entering the $1.5B DVT market. With a strategic distribution partnership, Therma Bright is poised for rapid growth in medical devices and therapies.


Click to follow <a href="https://stocktwits.com/symbol/TBRIF">Therma Bright, Inc. </a>(TSXV: THRM) (<a href="https://stocktwits.com/symbol/TBRIF">OTCQB: TBRIF</a>) (FSE: JNX)A burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:- Managing symptoms of post-thrombotic syndrome (PTS)- Preventing primary thrombosis- Treating lymphedema- Reducing post-operative pain and swelling- Alleviating leg swelling caused by vascular insufficiency- Treating varicose veins- Managing chronic venous insufficiency- Enhancing blood circulation- Addressing intermittent claudication&nbsp;All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

<h1>Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market</h1><h2>Therma Bright (THRM) secures permanent Medicare and Medicaid reimbursement codes for Venowave VW5, making it the only product with reimbursement codes in deep vein thrombosis (DVT) market, expected to grow in value to US $1.55 billion by 2032.</h2>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/therma-bright">Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX)</a>, a leader in proprietary diagnostic and medical device technology, is making significant strides in addressing critical health challenges with its innovative solutions. The company’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">latest achievement</a>, the permanent Healthcare Common Procedure Coding System (HCPCS) code E0683 for its Venowave VW5 device, marks a crucial milestone in enhancing patient care and expanding market reach.<h3>Venowave VW5: A Revolutionary Approach to Circulatory Health</h3>The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/venowave/">Venowave VW5</a> is a first-of-its-kind piece of Durable Medical Equipment designed to treat and prevent deep vein thrombosis (DVT) and other circulatory issues by utilizing a series of compact, battery-operated peristaltic pumps that generate a wave-form motion.Worn below the knee and strapped firmly to the calf, the Venowave device provides compression to the calf and creates an increased upward volumetric displacement of venous and lymph fluid, resulting in improved vascular and lymphatic flow in the lower limbs.The device, now recognized by the U.S. Department of Health &amp; Human Services’ Centers for Medicare and Medicaid Services (CMS) with its own HCPCS code, offers patients a much-needed alternative to traditional treatments like compression socks. Unlike compression socks, which can cause discomfort and skin issues, the Venowave VW5 uses its wave-form motion to gently massage the calf, improving blood circulation without the associated drawbacks.Rob Fia, CEO of Therma Bright, commented on the milestone announcement, stating:<blockquote>“We’re pleased that the Centers for Medicare and Medicaid has approved our permanent code request, as well as the reimbursement pricing and the new HCPCS Level II designation for our Venowave VW5 device. As shared in several of our recent press announcements, the CDC estimates that over 900,000 U.S. citizens suffer from deep vein thrombosis (DVT) and MarketDigit’s research projected this disease will ‘reach USD 1.5 Billion by 2032’ on a global market value perspective. And DVT is only one medical condition area out of ten circulatory issues that the permanent code will cover, which is very exciting.”</blockquote>The reimbursable codes are not only a great opportunity for Therma Bright but also for the company’s customers, reseller partners and shareholders.The Medicare and Medicaid codes for the Venowave VW5 cover the following ten indications:– Prevention of deep vein thrombosis (DVT) – Management of the symptoms of post-thrombotic syndrome (PTS) – Prevention of primary thrombosis – Treatment of lymphedema – Diminishing post-operative pain and swelling – Treatment of leg swelling due to vascular insufficiency – Treatment of varicose veins – Treatment of chronic venous insufficiency – Enhancing blood circulation – Treatment of intermittent claudicationPer this morning’s Therma Bright&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">press release</a>, the Venowave VW5 will have a complete patient buyout option for a pair of Venowave devices with a capped reimbursement of $1,199.The Venowave VW5 can also be rented with a capped rental fee reimbursement of $78.05 per month. The total capped rental reimbursement payment for 13 months of continuous use is $819.55, and following the 13th rental payment, the patient will become the owner of the Venowave VW5.The device’s impact is underscored by the growing need for effective DVT treatments. The global market for DVT prevention is&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/en/news-release/2024/01/29/2819535/28124/en/Deep-Vein-Thrombosis-Market-Projected-to-Ascend-to-1-26-billion-by-2028-A-Fresh-Global-Market-Report-Unveiled.html">projected to grow</a> steadily at a CAGR of 4.1% and reach US $1.26 billion by 2028 and US $1.55 billion by 2032, driven by an aging population and the increasing prevalence of lifestyle diseases like obesity. With over 900,000 Americans affected by DVT annually, the Venowave VW5 is poised to play a critical role in managing and preventing this life-threatening condition.Highlighting the significance of the development, Fia added:<blockquote>“This innovative device for addressing DVT and these other blood circulation issues is the first-of-its-kind to receive the permanent HCPCS Level II code, and we look to provide an initial sales update on our solution in the coming week. One key competitive product in the marketplace is the compression sock, which applies controlled and constant pressure on the leg to improve blood flow in the veins. Unfortunately, users of the compression socks can experience a variety of challenges, including difficulty in putting the sock on, discomfort from constant pressure, minor bruising, skin ulcers, dry skin, redness, and itching. In contrast, the Venowave VW5 simply straps on and massages the leg, applying appropriate pressure in a comfortable and soothing manner to circulate blood through the veins.”</blockquote><h3>Expanding the Portfolio: AI-Powered Solutions and Strategic Investments</h3><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/">Therma Bright</a>‘s commitment to innovation extends beyond the Venowave VW5. The company is also at the forefront of integrating artificial intelligence (AI) into healthcare, as demonstrated by its Digital Cough Technology (DCT). Developed in partnership with&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/ai4lyf/">AI4LYF</a>, this AI-powered platform is currently&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220173/Therma-Brights-AIPowered-Digital-Cough-Technology-Being-Considered-as-Partner-Technology-in-New-Chronic-Cough-Drug-Clinical-Trial">under consideration</a> for a U.S. clinical trial involving a new chronic cough drug. The DCT platform enables healthcare providers and epidemiologists to make more accurate and informed decisions by analyzing cough sounds, thereby improving the diagnosis and management of respiratory conditions.Fia explained:<blockquote>“Our DCT solution and data collection platform is ideally positioned for clinical studies like this one. It allows health practitioners to quickly address a patient’s respiratory issues, ultimately leading to better health outcomes.”</blockquote>Therma Bright’s strategic investments further solidify its position in the medical device industry. The company’s portfolio includes a stake in Inretio, which is revolutionizing ischemic stroke treatment with its innovative clot-retrieving device, PREVATM. This technology has shown promising results in early trials, achieving an 80% success rate compared to the 50% effectiveness of existing devices. Additionally, Therma Bright is developing inhaled statin therapies for asthma and COPD, offering a new approach to treating these widespread respiratory conditions.<h3>The Road Ahead: A Focus on Patient-Centered Innovation</h3>Therma Bright’s focus on patient-centred innovation is evident in its approach to product development and market expansion. The company’s Venowave VW5 not only provides a new standard in DVT treatment but also sets the stage for further advancements in circulatory and respiratory health.As the healthcare landscape continues to evolve, Therma Bright is well-positioned to lead the way with its cutting-edge technologies. With the Venowave VW5 already making waves in the market and its AI-powered DCT platform on the brink of clinical integration, the company is poised to make a lasting impact on the health and well-being of millions.<h3>Therma Bright (TSXV: THRM) Stock Price Action</h3>Shares of Therma Bright stock are in the midst of an epic breakout, with THRM stock up as much as&nbsp;350% since July 31, 2024, and as much as&nbsp;800% since May 31, 2024.Therma Bright stock last traded at $0.085. YTD, THRM stock is up&nbsp;183.33%.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_20_at_7_52_22_PM_ae153f1a0d.png" alt="Screenshot 2024-08-20 at 7.52.22 PM.png" width="1436" height="864">Therma Bright, (TSXV: THRM), six-month interactive stock chart. (Source: Barchart)<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/stocks/quotes/THRM.VN/interactive-chart">View Therma Bright Stock Chart on Barchart</a>Read Next:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/biotech/tempest-therapeutics-tpst-stock-jumps-83-on-fda-phase-3-trial-news/">Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.comTherma Bright Inc. (CSE: PAID) is a paid client of Wealthy VC. This report/release/profile is a commercial advertisement and is for general information purposes only.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market

Therma Bright secures Medicare codes for its Venowave VW5, boosting its market presence in the $1.5B DVT market and driving an 800% stock surge since May 2024.

Therma Bright Gains Medicare Code for Venowave, Stock Soars

Equity

Therma Bright (TSXV: THRM) secures permanent Medicare and Medicaid reimbursement codes for its Venowave VW5 device, making it the only DVT treatment with such codes. This innovation has driven significant stock gains, with shares rising over 800% since May 2024.

Therma Bright, Inc. engages in developing and marketing skin care medical device products. Its products include Therapik, which is used to relieve the pain, itch and inflammation of stings and bites from different species of insects and InterceptCS, which is a device to prevent cold sore outbreaks. The company was founded in 2001 and is headquartered in Toronto, Canada.

Current Price	$0.0521
Prev Close	$0.0443
Open	$0.0521
Dividend Yield	0.00%
50-Day Moving Average	$0.0537
Beta	0.64
Avg. Volume	29,357.67
PE Ratio	-0.92

52-Week High	$0.5088
52-Week Low	$0.0392
Market Capitalization	$2.52M
EPS (Annual)	-$0.0453
Price to Book	3.05
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

TBRIF
Therma Bright Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TBRIF News

TBRIF Therma Bright Inc